Lung Cancer Surgery Market

Global Lung Cancer Surgery Market Forecast

The global lung cancer surgery market is expected to be valued at US$ 5.40 Billion in 2026 and is projected to reach US$ 6.69 Billion by 2033, growing at a CAGR of 3.1% between 2026 and 2033. The U.S. Preventive Services Task Force's 2021 expansion of lung cancer screening eligibility lowering the age threshold from 55 to 50 and reducing pack-year criteria continues to push early-stage diagnosis rates upward, directly increasing surgical candidacy. Per World Health Organization data, lung cancer remains the leading cause of cancer mortality globally at approximately 1.8 million deaths annually, underscoring persistent clinical demand that sustains this growth trajectory through 2033.

Key Highlights

• North America holds a 35.2% market share due to strong surgical infrastructure, expanded screening programs, and sustained investment in robotic surgery platforms.
• Asia Pacific is projected to grow at a CAGR of 9.8%, driven by expanding lung cancer screening initiatives and improved reimbursement policies for minimally invasive surgeries.
• Lobectomy accounts for 52.8% of the market as it remains the standard curative procedure for early-stage non-small cell lung cancer (NSCLC).
• Robotic-Assisted Thoracic Surgery is the fastest-growing segment as increasing competition among robotic platform providers is reducing adoption costs for hospitals.
• Sublobar resection is emerging as a key growth opportunity, supported by rising detection of early-stage IA1 lung cancers eligible for tissue-sparing surgical procedures.

Key Growth Determinants

• Expanded Low-Dose CT Screening Coverage Driving Surgical Volume

Early-stage lung cancer detection through low-dose CT programmes converts a greater proportion of patients into surgical candidates, directly expanding procedure volumes across hospital systems. The Centers for Medicare & Medicaid Services (CMS) expanded coverage for lung cancer screening in 2023 to include individuals aged 50–77 with a 20-pack-year smoking history, broadening access to an estimated 14.5 million newly eligible Americans.

Over the next two to three years, as screening pipelines mature and detection-to-surgery conversion rates stabilise, thoracic surgery programmes at academic medical centres and integrated delivery networks will absorb meaningfully higher caseloads, sustaining procedure-based revenue growth.

Key Growth Barrier

• Reimbursement Compression and Coding Disputes Suppressing Margin Expansion

Payer-driven reimbursement compression on thoracic surgery codes directly erodes procedure profitability, particularly for open and VATS lobectomy, where hospital margins are already thin. The Centers for Medicare & Medicaid Services reduced relative value units (RVUs) for several thoracic CPT codes in its 2024 Physician Fee Schedule Final Rule, creating a direct revenue headwind for high-volume thoracic programmes.

Incumbent hospital systems with diversified surgical service lines absorb these cuts more effectively, whereas standalone thoracic surgery centres face existential margin pressure that may force consolidation or affiliation with larger health networks.

Lung Cancer Surgery Market Opportunity

• Emerging Market Screening Infrastructure Build-Out Opening New Surgical Capacity

Health ministries across East and South Asia are actively funding CT screening infrastructure, creating a first-mover window for surgical device manufacturers, training programme providers, and hospital management companies to establish clinical partnerships before domestic capacity fully develops. China's National Programme for Cancer Prevention and Control (2023–2030), launched by the National Health Commission of the People's Republic of China, explicitly targets a 35% reduction in premature cancer mortality, with lung cancer screening at its operational core.

Companies that embed training academies, service contracts, and consumable supply agreements into these nascent programmes now will secure long-cycle revenue streams as surgical volumes ramp toward Western utilisation benchmarks over the 2026–2033 period.

Market Segmentation Analysis

• Procedure Type Analysis

Lobectomy accounts for 52.8% of the global lung cancer surgery market in 2026, equivalent to US$ 2.85 Billion, sustaining its dominance because it remains the oncological gold standard for resectable stage I–II non-small cell lung cancer in patients with adequate pulmonary reserve.

Thoracic surgery programmes at institutions such as MD Anderson Cancer Center and the Mayo Clinic anchor their lung cancer protocols around lobectomy, with multidisciplinary tumour boards consistently selecting it for centralised or peripheral tumours with adequate margins. The procedure's reimbursement profile under Medicare MS-DRG 163–165 (major thoracic procedures) also sustains hospital revenue concentration in this code cluster, reinforcing surgical team specialisation.

Segmentectomy is the fastest growing procedure type, propelled directly by the JCOG0802 trial's confirmation of non-inferiority for small peripheral tumours and the subsequent NCCN guideline revision in 2023. Intuitive Surgical's expansion of robotic platform training modules specifically for anatomic segmentectomy including fissure-first and intersegmental plane identification techniques is accelerating adoption at robotic-equipped programmes targeting stage IA1 patients, a newly addressable cohort.

• Surgical Approach Analysis

Video-Assisted Thoracoscopic Surgery (VATS) accounts for 44.9% of the global lung cancer surgery market in 2026, equivalent to US$ 2.42 Billion, leading because it delivers the clinical benefits of minimally invasive resection at a significantly lower capital and per-procedure cost than robotic platforms, making it the default minimally invasive choice at the broadest range of hospital settings globally.

In the United Kingdom, NHS England's Getting It Right First Time (GIRFT) programme for thoracic surgery has explicitly benchmarked VATS lobectomy as the preferred approach at high-volume centres, driving procedure mix shifts across NHS trusts since the programme's thoracic surgery report was published in 2022. The procedure's established training pathway through European Society of Thoracic Surgeons (ESTS) competency frameworks further cements its institutional penetration.

Robotic-Assisted Thoracic Surgery (RATS) is the fastest growing surgical approach, driven by Medtronic's launch of the Hugo RAS system receiving CE Mark for thoracic applications in 2023 which introduced a second credible robotic platform to compete with Intuitive Surgical, reducing single-vendor dependency and accelerating hospital adoption decisions across European and Asia Pacific markets.

• Cancer Type Analysis

Non–Small Cell Lung Cancer (NSCLC) accounts for 86.3% of the global lung cancer surgery market in 2026, equivalent to US$ 4.66 Billion, dominating because NSCLC's adenocarcinoma and squamous cell subtypes are surgically resectable at early stages, whereas the disease's natural history presenting as localised, well-demarcated lesions aligns with curative lobectomy and segmentectomy protocols.

Academic thoracic oncology centres treat NSCLC surgical patients through structured pathways integrating PET-CT staging, EBUS-guided mediastinal sampling, and anatomic resection, with institutions such as Memorial Sloan Kettering Cancer Center reporting NSCLC surgical volumes exceeding 400 cases annually. The FDA's approval of adjuvant osimertinib (Tagrisso, AstraZeneca) in 2020 for resected EGFR-mutated NSCLC has further reinforced surgical resection as a necessary component of curative-intent treatment.

Small Cell Lung Cancer (SCLC) is the fastest growing segment, driven by emerging clinical evidence supporting surgical resection in very limited-stage (T1–T2, N0) SCLC. Bristol-Myers Squibb's ongoing exploration of perioperative immunotherapy combinations for resectable SCLC building on the CheckMate programme data is creating a newly addressable surgical cohort among patients previously treated exclusively with chemoradiation.

Regional Insights

• North America Lung Cancer Surgery Market Trends and Insights

North America accounts for 35.2% of the global lung cancer surgery market in 2026, representing US$ 1.90 Billion, anchored by the United States' high per-capita healthcare expenditure, mature thoracic surgical infrastructure, and the CMS-driven expansion of lung cancer screening eligibility.

The American College of Chest Physicians and American Thoracic Society jointly maintain clinical practice guidelines that standardise surgical referral pathways, ensuring consistent procedural volumes across academic and community health systems. The region's insurance coverage architecture including Medicare Part A inpatient surgical benefits sustains high case conversion rates from screen-detected lesions to resection.

United States Lung Cancer Surgery Market Size

The United States lung cancer surgery market represents 89.3% of the North America regional market in 2026, equivalent to US$ 1.70 Billion. The National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) programme estimates approximately 14% of lung cancer cases are diagnosed at a localised stage where surgery remains the primary curative modality, generating consistent annual procedure demand across 2,200+ hospital-based thoracic surgery programmes nationwide.

As the Veterans Health Administration accelerates its lung cancer screening rollout across 170+ medical centres, surgical referral pipelines within the VA system represent a structurally underpenetrated volume opportunity through 2030.

• Asia Pacific Lung Cancer Surgery Market Trends and Insights

Asia Pacific accounts for 24.9% of the global lung cancer surgery market in 2026, representing US$ 1.34 Billion, and is the fastest growing region at a CAGR of 9.8%, driven by the confluence of the world's highest absolute lung cancer incidence burden, rapidly expanding hospital infrastructure, and government-funded screening programme deployments. China and Japan together account for the majority of regional surgical volume, but South Korea's National Health Insurance Service reimbursement expansions for VATS procedures since 2022 are creating meaningful incremental case growth in a high-income, high-capacity market. Universal health coverage expansion across Southeast Asian middle-income economies will sustain the region's outperformance relative to the global CAGR through 2033.

China Lung Cancer Surgery Market Size

The China lung cancer surgery market represents 38.5% of the Asia Pacific regional market in 2026, equivalent to US$ 0.52 Billion. China reports the world's highest absolute lung cancer incidence approximately 870,000 new cases annually per the International Agency for Research on Cancer (IARC) and the National Cancer Center of China is coordinating a multi-city CT screening roll-out targeting high-risk urban populations, which will accelerate early-stage surgical referrals materially by 2028.

Japan Lung Cancer Surgery Market Size

The Japan lung cancer surgery market represents 19.4% of the Asia Pacific regional market in 2026, equivalent to US$ 0.26 Billion. Japan's Ministry of Health, Labour and Welfare has incorporated lung cancer screening into its national cancer control plan, and the country's world-leading surgical quality infrastructure including the Japanese Association for Chest Surgery registry tracking outcomes across more than 80,000 thoracic cases annually positions it as the region's benchmark for minimally invasive technique adoption.

 Japan's aging demographic profile, with more than 29% of its population aged 65 or older per Statistics Bureau of Japan data, sustains structural demand growth independent of screening programme expansion.

India Lung Cancer Surgery Market Size

The India lung cancer surgery market represents 12.8% of the Asia Pacific regional market in 2026, equivalent to US$ 0.17 Billion. Tata Memorial Centre in Mumbai and the All India Institute of Medical Sciences (AIIMS) in New Delhi anchor the country's high-acuity thoracic surgery capacity, together performing an estimated several hundred complex lung resections annually at heavily subsidised rates under India's Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PM-JAY) scheme.

As private hospital networks such as Fortis Healthcare and Apollo Hospitals expand their thoracic oncology departments in Tier 1 and Tier 2 cities, the addressable surgical market will broaden beyond the current concentration in government academic centres, with a decisive volume inflection expected post-2027.

Competitive Landscape

The global lung cancer surgery market operates as a provider-concentrated, technology-enabled services market where clinical reputation, surgical volume, and platform access determine competitive positioning rather than conventional product differentiation. MD Anderson Cancer Center, Mayo Clinic, and Memorial Sloan Kettering Cancer Center function as volume anchors and protocol setters domestically, while internationally Ramsay Health Care and Spire Healthcare Group plc represent the leading private operators scaling minimally invasive thoracic programmes across multi-site networks.

The dominant strategic theme is robotic programme investment, where first-movers in RATS lobectomy are capturing higher-acuity referrals from community hospitals. HCA Healthcare, operating the largest for-profit hospital network in the United States, represents the most disruptive force through sheer scale its ability to standardise VATS and robotic protocols across 180+ hospitals creates procurement leverage and outcomes data that smaller systems cannot replicate. 

Companies Covered in Lung Cancer Surgery Market

• HCA Healthcare
• Cleveland Clinic
• Chesapeake Regional Health
• Mayo Clinic
• MD Anderson Cancer Center
• Ramsay Health Care
• Spire Healthcare Group plc
• Fortis Healthcare
• National Cancer Center Japan
• Tata Memorial Centre
• Memorial Sloan Kettering Cancer Center
• Apollo Hospitals Enterprise Ltd.
• IHH Healthcare Berhad
• Bumrungrad International Hospital
• Keck Medicine of USC
• University of Texas Southwestern Medical Center
• Asahi General Hospital

Market Segmentation

By Procedure Type

• Lobectomy
• Segmentectomy
• Pneumonectomy
• Others

By Sugical Approach

• Open Surgery
• Video-Assisted Thoracoscopic Surgery (VATS)
• Robotic-Assisted Thoracic Surgery (RATS)

By Cancer Type

• Non–Small Cell Lung Cancer (NSCLC)
• Small Cell Lung Cancer (SCLC)

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa